AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 33,762 AI briefs of material SEC Form 8-K filings by 4,789 companies: 2,376 written within three weeks of the filing (filed since Oct 19, 2026) and 31,386 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record33,762every one kept
Companies4,789with at least one brief
Recent filings2,376filed since Oct 19, 2026
Past filings31,386written later, in Nov 2026
Scholar Rock agreed on November 9, 2026, to sell a Rare Pediatric Disease Priority Review Voucher to BioNTech US Inc. for $205 million in cash, payable at closing, which remains subject to customary conditions including the Hart-Scott-Rodino waiting period. The same day it reported third-quarter results, with its first ISEMBYLD product revenue of $0.6 million offset by a wider net loss of $107.2 million.
- Buyer BioNTech US Inc. agreed to pay $205 million in cash at closing for the voucher, awarded after the September 11, 2026 FDA approval of ISEMBYLD
- Q3 2026 net product revenue was $0.6 million, versus none in Q3 2025
- Q3 2026 net loss was $107.2 million, or $0.81 per share, compared with a net loss of $102.2 million, or $0.90 per share, a year earlier
- Cash, cash equivalents and marketable securities were $413.6 million as of September 30, 2026
Read the filing on SEC.gov ↗
Palladyne AI reported third-quarter 2026 revenue of $8.6 million, up from $0.9 million a year earlier, and raised the low end of its full-year 2026 revenue guidance to $25.0 million while keeping the top end at $27.0 million. The GAAP net loss widened to $12.0 million, or $0.25 per share, from $3.7 million, or $0.09 per share, in the prior-year quarter. Shareholders also face a 9% reduction in fully diluted shares after warrants and contingent shares expired on September 24, 2026.
- Q3 2026 revenue was $8.6 million versus $0.9 million in Q3 2025, and up 48% sequentially.
- GAAP net loss was $12.0 million ($0.25 per share) versus $3.7 million ($0.09 per share) a year earlier.
- Full-year 2026 revenue guidance is now $25.0 million to $27.0 million, up from a prior low end, and backlog was $18.7 million as of September 30, 2026.
- All 20.5 million warrants and 2.3 million remaining contingent merger consideration shares expired on September 24, 2026; cash, equivalents and marketable securities were $47.0 million.
Read the filing on SEC.gov ↗
Sionna Therapeutics reported a third-quarter 2026 net loss of $32.4 million, up from $20.3 million a year earlier, as research and development and general and administrative expenses rose. The company cut its workforce by about 46% in September 2026 and is not advancing SION-719 after its PreciSION CF Phase 2a trial missed its key activity endpoint, focusing instead on SION-451 + SION-2222, with a Phase 2 trial planned for the first quarter of 2027. Cash, cash equivalents and marketable securities were $249.8 million at September 30, 2026, which the company expects to fund operations into the second half of 2029.
- Net loss was $32.4 million, or $0.72 per share, for the quarter ended September 30, 2026, compared with $20.3 million, or $0.46 per share, a year earlier.
- R&D expenses were $22.0 million and G&A expenses were $12.8 million, up from $16.0 million and $7.8 million in the prior-year quarter.
- Cash, cash equivalents and marketable securities totaled $249.8 million, down from $310.3 million at December 31, 2025.
- The AscenSION CF Phase 2 proof-of-concept trial of SION-451 + SION-2222 is expected to start in the first quarter of 2027.
Read the filing on SEC.gov ↗
908 Devices reported third-quarter 2026 revenue of $19.0 million, up 35% from a year earlier, and a net loss from continuing operations of $4.6 million, down from $14.9 million. The company raised the low end of its full-year 2026 revenue guidance to $68.5 million to $70.0 million. A $11.0 million noncash reduction in contingent consideration expense helped narrow the loss, and the company reported no debt outstanding.
- Q3 2026 revenue was $19.0 million, up from $14.0 million a year earlier; GAAP gross margin was 53%, unchanged from the prior year.
- Operating expenses fell to $15.5 million from $23.7 million, mainly due to an $11.0 million noncash reduction in contingent consideration expense.
- 2026 revenue guidance is now $68.5 million to $70.0 million, up from $68.0 million to $70.0 million at the low end.
- Cash and marketable securities were $99.1 million as of September 30, 2026, with no debt outstanding.
Read the filing on SEC.gov ↗
Enova International's Board authorized a new share repurchase program of up to $500 million, expiring June 30, 2028. The new program replaces the existing $400 million program, which would have expired June 30, 2027. The filing says the company is not obligated to buy any shares and the Board may change or end the program at any time.
- New repurchase authorization of up to $500 million, described as the largest in Enova's history
- Program expires June 30, 2028; replaces the $400 million program that would have expired June 30, 2027
- Repurchases may be made in the open market or through privately negotiated transactions; no obligation to buy
Read the filing on SEC.gov ↗
Liquidia reported a third-quarter 2026 net loss of $236.3 million, or $2.64 per share, after a $389.7 million litigation settlement charge tied to its global settlement with United Therapeutics. Net product sales of YUTREPIA rose to $222.7 million from $51.7 million a year earlier, and non-GAAP adjusted EBITDA was $140.5 million. The settlement resolves all pending litigation with United Therapeutics, and Liquidia agreed to pay net $380.7 million in installments in 2026 and 2027.
- Q3 2026 net loss of $236.3 million, or $2.64 per share, versus a net loss of $3.5 million, or $0.04 per share, in Q3 2025
- Net product sales of $222.7 million, up 31% from Q2 2026 and up from $51.7 million in Q3 2025
- Adjusted EBITDA of $140.5 million, the fifth consecutive quarterly increase; cash and cash equivalents were $396.1 million before settlement payments
- Global settlement with United Therapeutics dated October 13, 2026, with Liquidia agreeing to pay net $380.7 million in 2026 and 2027
Read the filing on SEC.gov ↗
Harvard Bioscience filed an investor presentation dated November 2026 that reports third-quarter 2026 revenue of $22.2 million, up 8% from a year earlier, but adjusted EBITDA of $1.8 million, down from $2.0 million. The company lowered its full-year 2026 adjusted EBITDA growth outlook to (1)% to 4% from 6% to 10%, while its 3% to 5% revenue growth outlook is shown without a stated change.
- 3Q26 revenue $22.2 million vs $20.6 million in 3Q25 (up 8%); 3Q26 GAAP diluted loss per share $(0.58) vs $(0.28)
- 3Q26 adjusted EBITDA $1.8 million vs $2.0 million; adjusted EBITDA margin 7.9% vs 9.6%
- FY26 adjusted EBITDA growth outlook lowered to (1)% to 4%, from 6% to 10%; FY26 revenue growth outlook 3% to 5%
- 4Q26 outlook: revenue $23.7 million to $25.5 million; adjusted EBITDA $3.8 million to $4.2 million
Read the filing on SEC.gov ↗
Janus International Group reported third quarter 2026 revenue of $213.1 million, down 2.8% year-over-year, and a net loss of $13.3 million, or $(0.10) per diluted share, compared with net income of $15.2 million a year earlier. The company also updated its full year 2026 guidance, which now projects Adjusted EBITDA of $127 million to $133 million, a 22.7% decline at the midpoint from the prior year.
- Q3 2026 revenue was $213.1 million, down 2.8% year-over-year; self-storage revenue fell 5.0%.
- Net loss was $13.3 million, or $(0.10) per diluted share, including an $18.3 million impairment of goodwill and intangible assets.
- Adjusted EBITDA was $34.0 million, down 22.0% year-over-year, with a 16.0% margin.
- 2026 guidance: total revenue of $855 million to $865 million and Adjusted EBITDA of $127 million to $133 million.
Read the filing on SEC.gov ↗
WhiteFiber's indirect subsidiaries entered into a $300.0 million Term Loan Credit Agreement with Morgan Stanley Senior Funding and a lender group on November 9, 2026. No loans had been funded as of the filing date, and initial funding depends on conditions tied to the first 40 megawatts of the NC-1 data center in Madison, North Carolina. The loans are not guaranteed by WhiteFiber, Inc., but the financing adds debt tied to the project and includes covenants and a mortgage on the data center.
- Facilities: $200.0 million initial term loan and $100.0 million delayed-draw term loan, both maturing on the fifth anniversary of initial funding
- Interest at Term SOFR (2.00% floor) plus 6.00%, or base rate (3.00% floor) plus 5.00%, at the borrower's election
- No loans funded as of the filing; initial funding is scheduled within 30 days after closing, with up to two 30-day extensions
- Loans are not guaranteed by WhiteFiber, Inc.; the Operating Partnership must deliver an unsecured Phase 1 completion guarantee before initial funding
Read the filing on SEC.gov ↗
TransDigm reported fourth-quarter fiscal 2026 net sales of $2,988 million, up 23%, and EPS of $10.33, up 33%, while quarterly net income fell 4% to $586 million on higher interest and tax expense. The company also issued fiscal 2027 guidance calling for net sales of $11,950 million to $12,150 million and EPS of $42.06 to $42.91, which shareholders can compare against the fiscal 2026 results.
- Q4 net sales $2,988 million, up 23% from $2,437 million; EPS $10.33, up 33% from $7.75.
- Q4 net income $586 million, down $23 million or 4%; adjusted EPS $12.44, up 15% from $10.82.
- Fiscal 2027 guidance: net sales $11,950 million to $12,150 million; EPS $42.06 to $42.91; adjusted EPS $47.09 to $47.94.
- Company returned $943 million through buybacks in Q4 and $2.8 billion for fiscal 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.